NLRP3 and diabetes mellitus: It is considered that DPP-4 inhibitors prevent diabetes-induced activation of node like receptor family, pyrin domain containing 3 (NLRP3) inflammasome that causes metabolic inflammation and insulin resistance (35, 36).